Patent ID: 11921120
Assignee: DUKE UNIVERSITY
Field: Pharmaceuticals (Chemistry)
Classification: CPC G  A | IPC A  G

Claim 0:
1. A method of identifying a subject at risk for metabolic dysfunction, the method comprising:
(a) isolating a biosample from a subject;
(b) determining the level of one or more biomarkers present in the biosample, wherein the one or more biomarkers comprise
PlexinD1 nucleic acid or protein,
COL5A1 nucleic acid or protein, or
a combination thereof;

(c) identifying the subject as having a risk for metabolic dysfunction when the level of the one or more biomarkers is increased or decreased relative to a reference level or a range of reference levels of the same biomarker, and wherein the metabolic dysfunction is insulin sensitivity, insulin resistance, or type 2 diabetes; and
(d) treating the at-risk subject by administering to the subject an interfering molecule that (i) decreases the level or activity of the PlexinD1 nucleic acid or protein, or (ii) increases the level or activity of the COL5A1 nucleic acid or protein.